← Back to Search

Monoclonal Antibodies

ZL-1201 for Cancer

Phase 1
Waitlist Available
Research Sponsored by Zai Lab (Shanghai) Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 30 days after last dose
Awards & highlights

Study Summary

This trial is testing a new cancer drug to see if it is safe and effective.

Eligible Conditions
  • Advanced Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from the time of informed consent to 30 days after last dose
This trial's timeline: 3 weeks for screening, Varies for treatment, and from the time of informed consent to 30 days after last dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety and tolerability of ZL-1201 when administered as an intravenous (IV) infusion: Incidence of Treatment-Emergent Adverse Events
Secondary outcome measures
Immunogenicity
Overall Response Rate (ORR）
Pharmacokinetics: CL
+4 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Single arm, ZL-1201Experimental Treatment1 Intervention
Single arm, ZL-1201
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ZL-1201
2020
Completed Phase 1
~40

Find a Location

Who is running the clinical trial?

Zai Lab (Shanghai) Co., Ltd.Lead Sponsor
28 Previous Clinical Trials
3,589 Total Patients Enrolled
Study PhysicianStudy DirectorZai Laboratory
7 Previous Clinical Trials
2,611 Total Patients Enrolled
~7 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top